However, several studies showed that DLL3 is highly expressed in small cell lung carcinoma (SCLC) and other neuroendocrine cells neoplasm, which offers potential for DLL3-targeted therapeutic design [7, 8]. This evidence concerns the gene DLL3 and small cell lung carcinoma.